Rongrui Liu
About
Rongrui Liu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Rongrui Liu has authored 30 papers receiving a total of 767 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in Rongrui Liu's work include Cancer Immunotherapy and Biomarkers (9 papers), Gastric Cancer Management and Outcomes (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). Rongrui Liu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Gastric Cancer Management and Outcomes (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). Rongrui Liu collaborates with scholars based in China, United States and France. Rongrui Liu's co-authors include Ru Jia, Lianpeng Chang, Xin Yi, Gairong Zhang, Jian-Ming Xu, Yan Wang, Zhiyuan Hu, Yun Zhang, Quanren Wang and Jianming Xu and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and European Journal of Cancer.
In The Last Decade
Rongrui Liu
29 papers receiving 761 citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Rongrui Liu China | 12 | 513 | 288 | 159 | 153 | 149 | 30 | 767 | ||
| C.J.A. Punt Netherlands | 11 | 299 0.6× | 216 0.8× | 171 1.1× | 69 0.5× | 75 0.5× | 26 | 624 | ||
| Kristen Spencer United States | 14 | 506 1.0× | 286 1.0× | 76 0.5× | 80 0.5× | 140 0.9× | 59 | 924 | ||
| Joanne Wing Yan Chiu China | 10 | 408 0.8× | 132 0.5× | 195 1.2× | 81 0.5× | 55 0.4× | 22 | 647 | ||
| Daniel Oruzio Germany | 14 | 426 0.8× | 149 0.5× | 60 0.4× | 96 0.6× | 72 0.5× | 30 | 658 | ||
| Jiachang Chi China | 18 | 357 0.7× | 227 0.8× | 277 1.7× | 48 0.3× | 64 0.4× | 49 | 943 | ||
| Koji Takami Japan | 19 | 348 0.7× | 665 2.3× | 112 0.7× | 58 0.4× | 99 0.7× | 72 | 1.1k | ||
| Katharina Balschun Germany | 8 | 260 0.5× | 107 0.4× | 53 0.3× | 99 0.6× | 130 0.9× | 8 | 619 | ||
| Miangela M. Laclé Netherlands | 18 | 544 1.1× | 388 1.3× | 38 0.2× | 196 1.3× | 79 0.5× | 58 | 991 | ||
| Ingvild Moberg Norway | 5 | 426 0.8× | 175 0.6× | 270 1.7× | 114 0.7× | 90 0.6× | 8 | 662 | ||
| Gerry Gin Wai Kwok China | 7 | 343 0.7× | 109 0.4× | 107 0.7× | 55 0.4× | 51 0.3× | 10 | 518 |
Countries citing papers authored by Rongrui Liu
Since
Specialization
Citations
This map shows the geographic impact of Rongrui Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rongrui Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rongrui Liu more than expected).
Fields of papers citing papers by Rongrui Liu
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Rongrui Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rongrui Liu. The network helps show where Rongrui Liu may publish in the future.
Co-authorship network of co-authors of Rongrui Liu
This figure shows the co-authorship network connecting the top 25 collaborators of Rongrui Liu. A scholar is included among the top collaborators of Rongrui Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rongrui Liu. Rongrui Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Wu, Xueling, et al.. (2025). Spatiotemporal Analysis of Eco-Geological Environment Using the RAGA-PP Model in Zigui County, China. Remote Sensing. 17(14). 2414–2414.
2.
Ye, Sisi, et al.. (2024). The Role of SPEN Mutations as Predictive Biomarkers for Immunotherapy Response in Colorectal Cancer: Insights from a Retrospective Cohort Analysis. Journal of Personalized Medicine. 14(2). 131–131.
3.
Lin, Rongbo, Jianming Xu, Rongrui Liu, et al.. (2024). An anti-EpCAM x anti-CD3 bispecific antibody, M701, for the treatment of malignant ascites due to epithelial cancer: Interim results of a prospective randomized controlled phase II trial.. Journal of Clinical Oncology. 42(16_suppl). 12060–12060.
4.
Zhao, Chuanhua, Rongrui Liu, Yan Wang, et al.. (2023). A combined immune prognostic index in esophageal squamous cell carcinoma patients treated with anti-PD-1 therapy. Therapeutic Advances in Medical Oncology. 15. 2619605–2619605.
5.
Liu, Rongrui, Xiujuan Qu, Nong Yang, Xiaoli Chai, & Jianming Xu. (2023). First-in-human study of ZG19018, targeting KRAS G12C, as monotherapy in patients with advanced solid tumors.. Journal of Clinical Oncology. 41(16_suppl). e15127–e15127.
6.
Xu, Jianming, Jieer Ying, Rongrui Liu, et al.. (2022). KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer. European Journal of Cancer. 178. 1–12.
7.
Liu, Rongrui, Lianke Liu, Chuanhua Zhao, et al.. (2021). Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study. BMC Gastroenterology. 21(1). 398–398.
8.
Li, Huiping, Rongrui Liu, Bin Shao, et al.. (2020). Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. Chinese Journal of Cancer Research. 32(3). 370–382.
9.
Wang, Yan, Chuanhua Zhao, Lianpeng Chang, et al.. (2019). Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer. EBioMedicine. 43. 261–269.
10.
Xu, Jianming, Rongrui Liu, Yi Ba, et al.. (2019). Phase I study of fluzoparib, a PARP1 Inhibitor in combination with apatinib and paclitaxel in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology. 37(15_suppl). 4060–4060.
11.
Xu, Jian-Ming, Yun Zhang, Ru Jia, et al.. (2018). Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study. Clinical Cancer Research. 25(2). 515–523.
12.
Xu, Jianming, Ru Jia, Yan Wang, et al.. (2018). A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors.. Journal of Clinical Oncology. 36(15_suppl). e15125–e15125.
13.
Xu, Jianming, Shukui Qin, Yun Zhang, et al.. (2018). A phase I, open, multiple dose, dose escalation and expansion study to evaluate the safety, tolerability, and pharmacokinetics of KN035 (anti-PD-L1 antibody) administered in subcutaneous injection as a single agent to Chinese subjects with advanced solid tumors.. Journal of Clinical Oncology. 36(15_suppl). e15138–e15138.
14.
Xu, Jian-Ming, Yan Wang, Youliang Wang, et al.. (2017). PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research. 23(16). 4602–4616.
15.
Liu, Rongrui, et al.. (2017). A high-efficiency grating coupler between single-mode fiber and silicon-on-insulator waveguide. Journal of Semiconductors. 38(5). 54007–54007.
16.
Xu, Jianming, Yingxin Li, Xing Sun, et al.. (2017). A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations. Investigational New Drugs. 35(4). 463–470.
17.
Ye, Han, et al.. (2017). 4×25 GHz uni-traveling carrier photodiode arrays monolithic with InP-based AWG demultiplexers using the selective area growth technique. Chinese Optics Letters. 15(8). 82301–82301.
18.
Zhao, Chuanhua, Lin Li, Jianzhi Liu, et al.. (2016). A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma. Oncotarget. 7(35). 57310–57316.
19.
Sun, Haiyan, Yong Chen, Xuan Zou, et al.. (2015). Occurrence of oral Candida colonization and its risk factors among patients with malignancies in China. Clinical Oral Investigations. 20(3). 459–467.
20.
Zhao, Chuanhua, Rongrui Liu, Lin Li, et al.. (2014). Diffuse alveolar hemorrhage after erlotinib combined with concurrent chemoradiotherapy in a patient with esophageal carcinoma.. Europe PMC (PubMed Central). 7(11). 4492–7.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by C.J.A. Punt Breakdown of academic impact, for papers by Kristen Spencer Breakdown of academic impact, for papers by Joanne Wing Yan Chiu Breakdown of academic impact, for papers by Daniel Oruzio Breakdown of academic impact, for papers by Jiachang Chi Breakdown of academic impact, for papers by Koji Takami Breakdown of academic impact, for papers by Katharina Balschun Breakdown of academic impact, for papers by Miangela M. Laclé Breakdown of academic impact, for papers by Ingvild Moberg Breakdown of academic impact, for papers by Gerry Gin Wai Kwok